Stem Cell Rejuvenation by Cdc42 Inhibition
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
54
NCT06379087
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Phase: Phase 2
Role: Lead Sponsor
Start: May 1, 2024
Completion: Dec 31, 2026
NCT07035860
Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
Phase: N/A
Start: Jun 16, 2025
Completion: Jun 15, 2028
Loading map...